Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-Interventional Study in Patients With Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) to Investigate the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden (PASS MCL-005)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03647124
Recruitment Status : Recruiting
First Posted : August 27, 2018
Last Update Posted : September 12, 2019
Sponsor:
Information provided by (Responsible Party):
Celgene

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This is a European multinational, retrospective, non-interventional study of patients with R/R MCL designed to further investigate the research objectives described below

The proposed study has two cohorts:

For Cohort 1, MCL patients in the Nordic countries (Denmark and Sweden) will be identified through electronic medical records (EMRs), enabling identification of R/R MCL patients. The cohort identified through EMRs at chosen hospitals will then be linked to the national health registries. Exposure to lenalidomide will be identified through prescription registers or medical chart review.

For Cohort 2, sites will be identified in other European countries where patients have been treated with lenalidomide for R/R MCL. Identification of sites will be completed through partnership with the European Mantle Cell Lymphoma (European MCL) Registry, Additional sites will be identified by Celgene and then assessed for feasibility and invited to participate in the R/R MCL PASS.

For both cohorts, only sites where lenalidomide treatment for R/R MCL is reimbursed will be selected for the study. All data will be collected retrospectively from identified patients following the first dose of lenalidomide treatment for up to 6 months including those patients who died within this data collection period.


Condition or disease Intervention/treatment
Lymphoma, Mantle-Cell Drug: Lenalidomide

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 560 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Non-interventional, Post-authorization Safety Study of Patients With Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden
Actual Study Start Date : October 2, 2018
Estimated Primary Completion Date : December 31, 2026
Estimated Study Completion Date : December 31, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Lenalidomide treated R/R-MCL patients in Denmark and Sweden
Retrospective data collection for Lenalidomide treated R/R-MCL patients from Nordic registries and national health databases
 Drug: Lenalidomide
Lenalidomide
Lenalidomide treated R/R-MCL patients in the rest of EU
Retrospective data collection for Lenalidomide treated R/R-MCL patients from sites in the rest of European Union
 Drug: Lenalidomide
Lenalidomide


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To quantify and characterize the event of TFR by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting. [ Time Frame: Approximately 8.5 years ]
    To quantify and characterize the event of TFR by tumor burden (assessed based on the last CT scan performed within a maximum of 2 months prior to initiation of administration of lenalidomide) in R/R MCL patients treated with lenalidomide in a real-world setting.


Secondary Outcome Measures :
  1. To quantify and characterize the proportion of early deaths by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting [ Time Frame: Approximately 8.5 years ]
    To quantify and characterize the proportion of early deaths (defined as deaths within 20 weeks of initial administration of lenalidomide) by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study population will consist of a retrospective cohort of R/R MCL patients who have commenced treatment with lenalidomide after 08 July 2016 (date marketing authorization was granted). Three datasets will be described for the study population and will form the basis of subsequent analyses: Population dataset, Treatment dataset, Outcomes dataset
Criteria

Inclusion Criteria:

  1. Received at least one dose of lenalidomide commencing after 08 July 2016 for the treatment of relapsed refractory mantle cell lymphoma.
  2. Informed consent of the patient or an authorized third person or authority, if required by law, given prior to data collection.
  3. Patient must be ≥18 years of age at the time of signing the informed consent form.

Exclusion Criteria:

1) Patients will be excluded if they were participating in an interventional clinical trial during the treatment period under observation in this Post Authorization Safety Study.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03647124


Contacts
Layout table for location contacts
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations
Layout table for location information
Austria
Salzburger Landeskliniken - Universitaetsklinikum Salzburg Recruiting
Salzburger, Austria, 5020
Landesklinikum Wiener Neustadt Recruiting
Wiener Neustadt, Austria, 2700
AKH Wien, Universitaetsklinik fuer Innere Medizin III Not yet recruiting
Wien, Austria, 1090
France
CHRU de Brest - Hopital Morvan Not yet recruiting
Brest, France, 29200
CHU de Caen, institut d'hematologie de basse Nomandie Not yet recruiting
Caen Cedex 9, France, 14033
Centre Hospitalier de Versailles André Mignot Not yet recruiting
Le Chesnay, France, 78157
Clinique Victor Hugo Not yet recruiting
Le Mans, France, 72015
Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Universitaire Pitie Salpetriere (Hopital Pitie-Salpetriere) Not yet recruiting
Paris, France, 75013
Centre Hospitalier de Saint-Quentin Not yet recruiting
Saint Quentin Picardie, France, 2321
Institut Universitaire du Cancer Toulouse - Oncopole Not yet recruiting
Toulouse Cedex 9, France, 31000
Germany
Gesundheitszentrum St. Marien Gmbh Not yet recruiting
Amberg, Germany, 92224
Studienzentrum Aschaffenburg Not yet recruiting
Aschaffenburg, Germany, 63739
Berufsausuebungsgemeinschaft Kiehl/Stein Not yet recruiting
Frankfurt/ Oder Brandenburg, Germany, 15236
Klinikum Garmisch-Partenkirchen Gmbh - Zentrum Fuer Innere Medizin Withdrawn
Garmisch-Partenkirchen Bavaria, Germany, 82467
Praxis fuer Haematolgie, Onkologie und Palliativmedizin Not yet recruiting
Leipzig, Germany, 04289
Greece
Private hospital "Iatriko Psychikou", Athens Not yet recruiting
Athens, Greece, 11525
General University Hospital of Athens "LAIKO", Athens Not yet recruiting
Athens, Greece, 11527
Metaxa Cancer Hospital, Athens Not yet recruiting
Piraeous, Greece, 18537
Theageneio General Hospital, Thessaloniki Not yet recruiting
Thessaloniki, Greece, 54007
Netherlands
HagaZiekenhuis van Den Haag - Juliana Kinderziekenhuis (JKZ) - Leyweg Recruiting
Den Haag, Netherlands, 2545 AA
Spain
Hospital universitario de Alava Recruiting
Alava País Vasco, Spain, 1009
Hospital Universitario 12 de Octubre Recruiting
Madrid, Spain, 28041
Hospital Regional Universitario Carlos Haya Recruiting
Malaga, Spain, 29730
Hospital de Orense Recruiting
Ourense, Spain, 32005
Complejo Hospitalario de Navarra Recruiting
Pamplona Navarra, Spain, 31008
Hospital Clínico Universiatrio de Salamanca Recruiting
Salamanca, Spain, 37007
Nuestra Senora de Valme Recruiting
Sevilla, Spain, 41014
Sponsors and Collaborators
Celgene
Investigators
Layout table for investigator information
Study Director: Philippe Arnaud, MD Celgene
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT03647124     History of Changes
Other Study ID Numbers: CC-5013-MCL-005
U1111-1213-1816 ( Registry Identifier: WHO )
EUPAS23366 ( Registry Identifier: EU PAS Register )
First Posted: August 27, 2018    Key Record Dates
Last Update Posted: September 12, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Celgene:
Mantle Cell Lymphoma
MCL
Revlimid
Non-Interventional
PASS
CC-5013
 Relapsed
Refractory
TFR
Tumor Flare Reaction
High Tumor Burden
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
 Lenalidomide
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents